Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
← catalyst calendarNCT06731478 · readout in 652 d
Sponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →. With Merck Sharp & Dohme LLC.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
726estimated
Sites
250
Countries
Argentina, Australia, Austria +23
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-27 | actual | When the study began enrolling |
| Primary completion | 2028-06-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-02-01 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Gastric Cancer
- Gastroesophageal Junction Cancer
Interventions
- Drug: Trastuzumab Deruxtecan — also filed as T-DXd, ENHERTU®, DS-8201a
- Drug: pembrolizumab — also filed as KEYTRUDA®
- Drug: Trastuzumab
- Drug: Chemotherapy
Primary outcome
what the primary-completion date above is the date OFProgression Free Survival (PFS)
measured From date of randomization to the date of radiographic disease progression or death due to any cause, up to 59 months
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed